Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

SIDMAK "AB-RATED" THEOPHYLLINE CONTROLLED-RELEASE APPROVED April 30, making the second generic competitor to Key/Schering's Theo-Dur. The approval covers Sidmak Labs' controlled-release theophylline tablets in 100, 200 and 300 mg strengths. Announcing the approval, Sidmak said that "well-controlled bioequivalency studies have demonstrated that all strengths of theophylline/Sidmak are completely interchangeable with Theo-Dur tablets." Sidmak submitted five bioequivalence studies to FDA that show its theophylline is bioequivalent to the Key/Schering product. Sidmak tested the 100 and 200 mg doses of its generic theophylline against Theo-Dur 100 and 200 mg doses in multiple-dose, two-way crossover studies. The 300 mg dose was tested using a once-daily administration and a twice-daily regimen. Another study investigated the effects of food on theophylline's absorption. Forest conducted similar bioequivalence studies with its generic controlled-release theophylline, Theochron, in support of the first "AB"-rated dosage forms for Key's Theo-Dur. The Forest products, marketed by its Inwood Labs subsidiary, have carried AB ratings since January 1989. Schering has challenged the bioequivalence of Forest's theophylline products in meetings with the FDA and through Theo-Dur promotions, which FDA determined were "false and misleading." Sidmak plans to begin shipping its theophylline product in approximately two weeks. The company said that its price for the theophylline tablets will be 25% to 30% less than the average wholesale price (AWP) for Theo-Dur. Sidmak noted that its product also will be competitively priced to Forest's AWP for Theochron. Sidmak's theophylline will be available in bottles of 100's, 500's and 1,000's.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts